Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
National Institutes of Health
Want a reminder before this closes?
We'll email you 3 days before the deadline. One email, then we stop.
Free. Verify your email, then we send one reminder only.
- Posted
- Mar 16, 2026
- Closes
- Jun 16, 2028 (in 609 days)
Similar opportunities open now
- Development and Testing of Novel Interventions to Improve HIV Prevention, Treatment, and Program Implementation for People Who Use Substances (R34 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Mar 2027
- Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Dec 2027
- Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed)Same funderOpenNational Institutes of HealthCloses Dec 2027
- Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)Same funderOpenNational Institutes of HealthCloses Aug 2028Up to $3M
- Early Stage Testing of Pharmacologic or Neuromodulatory Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)Same funderOpenNational Institutes of HealthCloses Oct 2027
Classification and identifiers
- Solicitation number
- PAR-27-053
- Assistance listing (CFDA)
- 93.279
Amount
Amount not listed here. Check the official program.
Who can apply
Local government agencies, Nonprofits, and State government agencies can all apply here. Check the eligibility details below to see if your organization fits.
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
About this opportunity
This Notice of Funding Opportunity (NOFO) uses a R61/R33 Phased Innovation Award mechanism to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying SUD, including fundamental brain function relevant to substance use. This NOFO is particularly designed to support exploratory/developmental projects requiring budgets that would exceed that allowed for the R21 mechanism (Neuroscience Research on Drug Abuse (R21 Clinical Trial Optional)